Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...

US FDA approves GSK’s Exdensur for the treatment of severe asthma: London, UK Thursday, December 18, 2025, 11:00 Hrs [IST] GSK plc announced that the US Food and Drug Administra ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

GSK's asthma drug Exdensur, the first biologic for twice-yearly dosing, gains FDA approval for severe asthma treatment.

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...